Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$264,700
+$5,484 QoQ
Shares Held
1,689
-0.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#1,197
of 1,603 holders
Holding Since
Dec 2020
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Capital Asset Advisory Services LLC holds $29,712,872 across 11 Drug Manufacturers - General names. NVS ranks #11 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
26,233 | $6,662,395 | |
| 2 | LLY |
ELI LILLY & Co
|
4,985 | $5,979,159 | |
| 3 | ABBV |
AbbVie Inc.
|
22,814 | $5,740,914 | |
| 4 | PFE |
Pfizer Inc
|
138,613 | $3,337,801 | |
| 5 | MRK |
Merck & Co., Inc.
|
23,955 | $3,078,217 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
46,813 | $2,697,365 | |
| 7 | AMGN |
Amgen Inc
|
1,448 | $524,349 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
4,064 | $513,445 |
All Filings in NVS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $264,700 | 1,689 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $259,216 | 1,697 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $283,322 | 2,055 | Shares | Sole | 2026-01-09 | |
| 2025-09-30 | $252,632 | 1,970 | Shares | Sole | 2025-10-02 | |
| 2025-06-30 | $265,253 | 2,192 | Shares | Sole | 2025-07-07 | |
| 2025-03-31 | $276,916 | 2,484 | Shares | Sole | 2025-04-09 | |
| 2020-12-31 | $102,739 | 1,088 | Shares | Sole | 2021-03-02 | |
| No filing history on record for this holder in this stock. | ||||||